Combination Therapy for CLL: What Evidence Do We Have?
William Wierda, MD, PhD
Fixed-Duration: A Patient-Captivating Standard of Care in CLL
Talha Munir, PhD
Thomas Kipps, MD, PhD
Combination Therapy in CLL: Identifying the Right Patient for the Right Treatment Approach
Fixed-Duration Therapy in the Relapsed/Refractory CLL Setting
Fixed-Duration vs Continuous-Dosing Approaches in CLL: Impact on QoL and Toxicity Risk
Overcoming Disease Progression in CLL: Evidence-Based Re-Treatment Considerations
Enhancing Treatment Strategies With Molecular Approaches in HER2+ Gastrointestinal Cancers
Josep Tabernero, MD, PhD
Sara Lonardi, MD
Zev A. Wainberg, MD
Advancements in GU Cancers: Key Data from AUA 2024
Jason Hafron, MD
Carissa Chu. MD
Optimal Sequencing of ADCs in Endocrine Refractory HR+/HER2- Metastatic Breast Cancer
Javier Cortes, MD, PhD
Komal Jhaveri, MD, FACP
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Evolving Trends in Germline Genetic Testing for Prostate Cancer
Real-World Sequencing and Survival in Locally Advanced Prostate Cancer
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.